NCT00782483

Brief Summary

Lasers are being used to treat Port Wine Stains (PWS), but the laser doesn't always work. Only about 10% of PWS can be completely cleared. The research team believes that the investigators can improve the response of PWS to laser therapy by using a computer program that the principal investigator of this study (Dr. Shafirstein PhD) has developed. The purpose of this study is to test the validity of this computer program. Personalized Interactive Laser Therapy (PILT) could significantly improve clinical outcomes of laser treatment of PWS.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
6

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Oct 2008

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2008

Completed
28 days until next milestone

First Submitted

Initial submission to the registry

October 29, 2008

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 31, 2008

Completed
3.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2012

Completed
1.8 years until next milestone

Results Posted

Study results publicly available

July 21, 2014

Completed
Last Updated

July 21, 2014

Status Verified

June 1, 2014

Enrollment Period

4 years

First QC Date

October 29, 2008

Results QC Date

January 6, 2014

Last Update Submit

June 19, 2014

Conditions

Keywords

DiagnosisPort Wine StainPWS

Outcome Measures

Primary Outcomes (1)

  • Average Laser Setting to be Used to Treat Port Wine Stains as Measured by Mathematical Calculations Based on Imaging and Temperature Analysis of Malformation.

    6 subjects were enrolled but no data was ever collected due to early termination of the study due to the PI's relocation.

    Three treatments up to one year, whichever is first

Interventions

FLIR Systems, Boston, MA. This is a non invasive passive thermal imaging device with less than minimal risk to subjects and staff.

Sclerolaser, Candela Corp., Wayland, MA. This laser is approved by the food and drug administration (FDA) for treating PWS lesions and will be used as labeled.

3dMD, Atlanta, GA. Approved by the food and drug administration (FDA) for imaging patients and will be used as labeled.

Eligibility Criteria

Age3 Months - 17 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Diagnosed with a PWS
  • At least one visible PWS measuring greater than or equal to 15 mm in diameter.
  • Information provided regarding alternative treatment methods, includig no treatment.
  • Reading, understanding, and signing of an informed consent document.
  • Children age 7 years or older has read, understood, and signed an assent document.
  • Agreement to participate in the study.
  • Agreement to return to at least 1 follow-up evaluation and treatment within 1 year after first treatment.
  • Zubrod performance status of 0 or 1 at screening.

You may not qualify if:

  • Inability or unwillingness of subject to participate in the study.
  • Inability or unwillingness of one parent or legal guardian of the subject to sign written informed consent document.
  • Subject can not return to at least 1 follow-up visit within 1 year, after the first treatment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Arkansas Children's Hospital

Little Rock, Arkansas, 72202, United States

Location

MeSH Terms

Conditions

Port-Wine StainDisease

Condition Hierarchy (Ancestors)

Skin AbnormalitiesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesSkin DiseasesSkin and Connective Tissue DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Limitations and Caveats

PI relocated and protocol was terminated, and no subject returned for treatment under protocol.

Results Point of Contact

Title
Dr. Gal Shafirstein
Organization
University of Arkansas for Medical Sciences/Arkansas Children's Hospital

Study Officials

  • Gal Shafirstein, PhD

    UAMS, ACH

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 29, 2008

First Posted

October 31, 2008

Study Start

October 1, 2008

Primary Completion

October 1, 2012

Study Completion

October 1, 2012

Last Updated

July 21, 2014

Results First Posted

July 21, 2014

Record last verified: 2014-06

Locations